Targeted cancer drugs finally living up to the hype

Targeted cancer drugs finally living up to the hype
Big pharmaceutical companies are backing so-called antibody-drug conjugates. (Image: Bloomberg)
Bloomberg
By Lisa JarvisCancer drugs that work like heat-seeking missiles to deliver chemicals directly to tumours are having a bit of a moment. Pharmaceutical companies, in need of assets to counter flagging sales, are making these so-called antibody-drug conjugates the technology of choice in oncology dealmaking, as illustrated by the recent US$10.1 billion (NZ$16.5b) acquisition of ImmunoGen by AbbVie.If that trend sounds vaguely familiar, you have probably been following the pharma industry for too long. The field has gone through waves of hype and i...

More Bloomberg

Will AI make lawyers richer or put them out of work?
Technology Opinion

Will AI make lawyers richer or put them out of work?

Lawyers could be with us for a while; it's just not clear how they'll get paid.

Bloomberg 07 Sep 2025
EU pushes ahead trade deal with South American nations
Bloomberg

EU pushes ahead trade deal with South American nations

Countries fear the deal’s impact on the European agricultural sector.

Bloomberg 06 Sep 2025
Doubts about SpaceX’s dominance? Look at this
Technology Opinion

Doubts about SpaceX’s dominance? Look at this

The success of the Starship test brings Musk’s dream of reaching Mars closer to reality.

Bloomberg 30 Aug 2025
Google is trying everything to sell AI to sceptics
Technology Opinion

Google is trying everything to sell AI to sceptics

Google’s AI features might reach a new and important audience.

Bloomberg 23 Aug 2025